MFDS — authorised 19 September 2016
- Marketing authorisation holder: SAREPTA THERAPEUTICS INC
- Status: likely_approved
🇰🇷 Exondys 51 in South Korea
MFDS authorised Exondys 51 on 19 September 2016
Marketing authorisation
Exondys 51 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in South Korea
Frequently asked questions
Is Exondys 51 approved in South Korea?
Yes. MFDS authorised it on 19 September 2016.
Who is the marketing authorisation holder for Exondys 51 in South Korea?
SAREPTA THERAPEUTICS INC holds the South Korean marketing authorisation.